| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12094-007-0043-2 |
| P698 | PubMed publication ID | 17462974 |
| P50 | author | Jose R. Murguía | Q57608370 |
| P2093 | author name string | M Menacho-Márquez | |
| P433 | issue | 4 | |
| P921 | main subject | Saccharomyces cerevisiae | Q719725 |
| P304 | page(s) | 221-228 | |
| P577 | publication date | 2007-04-01 | |
| P1433 | published in | Clinical and Translational Oncology | Q15754324 |
| P1476 | title | Yeast on drugs: Saccharomyces cerevisiae as a tool for anticancer drug research | |
| P478 | volume | 9 |
| Q37636367 | A Systems Biology Approach to Understanding the Mechanisms of Action of an Alternative Anticancer Compound in Comparison to Cisplatin. |
| Q41514492 | A model for the spatiotemporal organization of DNA replication in Saccharomyces cerevisiae. |
| Q26774351 | A novel approach to the discovery of anti-tumor pharmaceuticals: searching for activators of liponecrosis |
| Q38088803 | Baker's yeast as a tool for the development of antifungal drugs which target cell integrity - an update |
| Q39070181 | Characterizing the laulimalide-peloruside binding site using site-directed mutagenesis of TUB2 in S. cerevisiae |
| Q36299802 | Confirmation of the cellular targets of benomyl and rapamycin using next-generation sequencing of resistant mutants in S. cerevisiae |
| Q57980482 | Effect ofin vitrodigested cod liver oil of different quality on oxidative, proteomic and inflammatory responses in the yeastSaccharomyces cerevisiaeand human monocyte-derived dendritic cells |
| Q51565685 | Genetic engineering and molecular characterization of yeast strain expressing hybrid human-yeast squalene synthase as a tool for anti-cholesterol drug assessment. |
| Q47884901 | Improper protein trafficking contributes to artemisinin sensitivity in cells lacking the KDAC Rpd3p |
| Q64104067 | Possible Role of the Ca/Mn P-Type ATPase Pmr1p on Artemisinin Toxicity through an Induction of Intracellular Oxidative Stress |
| Q28757069 | Progress in metabolic engineering of Saccharomyces cerevisiae |
| Q42586969 | Quantitative- and phospho-proteomic analysis of the yeast response to the tyrosine kinase inhibitor imatinib to pharmacoproteomics-guided drug line extension. |
| Q28553891 | Reverse Chemical Genetics: Comprehensive Fitness Profiling Reveals the Spectrum of Drug Target Interactions |
| Q33955538 | Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro |
| Q33356241 | Selective inhibition of yeast regulons by daunorubicin: a transcriptome-wide analysis |
| Q89403466 | Targeting Cdc42 with the anticancer compound MBQ-167 inhibits cell polarity and growth in the budding yeast S. cerevisiae |
| Q33752761 | The Toxic Effects of Tetrachlorobisphenol A in Saccharomyces cerevisiae Cells via Metabolic Interference |
| Q49798156 | The Yeast Saccharomyces cerevisiae as a Model for Understanding RAS Proteins and their Role in Human Tumorigenesis |
| Q34460680 | The effect of bioactive compounds on in vitro and in vivo antioxidant activity of different berry juices |
| Q33968443 | The metal-coordinated Casiopeína IIIEa induces the petite-like phenotype in Saccharomyces cerevisiae |
| Q36907080 | Yeast techniques for modeling drugs targeting Bcl-2 and caspase family members |
| Q28383634 | Yeast toxicogenomics: genome-wide responses to chemical stresses with impact in environmental health, pharmacology, and biotechnology |
| Q28481716 | Yeasts acquire resistance secondary to antifungal drug treatment by adaptive mutagenesis |
Search more.